Stay updated with breaking news from டான் லாங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ex-Francis Parker student files suit over alleged teacher sex abuse 10news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 10news.com Daily Mail and Mail on Sunday newspapers.
Wednesday, May 12, 2021 Next week s European Commission webinar on SEP enforcement: speakers include USPTO s chief policy officer Mary Critharis (and yours truly, too) On Wednesday (May 19, 2021), the fifth webinar of the European Commission s popular series on standard-essential patent (SEP) topics will be held. Its title is Enforcement of Standard-Essential Patents - current bottlenecks and possible solutions. In a previous post I mentioned I was going to be among the speakers. Meanwhile, the EC s Directorate-General for the Internal Market (DG GROW) has published the agenda. After Judge Edgar Brinkman s (The Hague) welcome speech, Mary Critharis, the Chief Policy Offier and Director for International Affairs of the United States Patent & Trademark Office will deliver a keynote addressd. I m sure many of you will be as interested as I am in listening to Mrs. Critharis s speech. After a recent decision by the DOJ to downgrade an implementer-hostile policy statement ....
Operator Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and I ll be your operator for today s call. [Operator Instructions] I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin. Steven Rubis Investor Relations Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenex s business as well as a review of financial results for the first quarter of 2021. The news release detailing the results crossed the wire earlier this morning and is available on the company s website. A replay of this call will also be archived on the company website. During the conference call, the company will make projections or forward-looking statements regarding future events, including statements about financial, business and clinical milestones anticipated in fiscal year 2021 and beyond. We encourage you to review the company s past and future filings w ....
Transformative, leading allogeneic NKT cell platform technology expands Athenex s cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers, respectively Total potential consideration of $185 million, comprising $70 million upfront primarily in Athenex common stock, and $115 million in development milestones Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies. ....